Abshi aims to redefine drug discovery with its data-centric approach to generative AI. At first glance, it sounds like a bundle of buzzwords, but a deeper look reveals a unique strategy. Instead of simply testing promising molecules in a laboratory, Abshi begins with a specific disease target. Then, it uses generative AI to design potential protein-based drugs digitally before moving to physical trials.

Their comprehensive platform blends deep learning with a high-output wet lab to facilitate the design and validation of AI-driven drug candidates. The long-term goal? To streamline the journey from a target to a viable drug sequence, ideally with just a click. That’s an ambitious vision, but it seems more fitting for a decade-long timeframe than for quarterly earnings reports.

This isn’t uncharted territory. Absci previously acquired Denovium, an AI-focused company aimed at speeding up biopharmaceutical research and gene discovery, and has integrated its technology into their current operations.

Assessing Partnerships

A glance at a company’s workforce can tell you a lot, and Absci’s partnerships are impressive given its size. Collaborations with major pharmaceutical firms, tech-oriented biology companies, and leading academic institutions reflect significant confidence in this startup.

In 2022, they partnered with Merck to explore new biologic drug candidates, showcasing their value to a top-tier research organization. Recently, they formed a strategic alliance with PrecisionLife to combine their AI drug design capabilities with computational approaches for treating complex chronic illnesses.

Looking ahead, Absci is joining forces with Owkin to tackle challenging drug targets using advanced AI. This partnership feels more like a blend of specialized tools than a simple licensing deal.

More Than Just a Service Provider

Absci is not merely a service provider; it’s also developing its pipeline of AI-created drug candidates. This dual role is crucial as we envision 2036. If even one in-house program successfully navigates clinical trials, it could lead to lucrative royalties and product benefits from their proprietary drugs.

The focus has shifted to creating “breakthrough treatments designed with generative AI,” suggesting that the company is intentionally retaining its best innovations for internal development rather than outsourcing everything.

The Risks of a Time Capsule Investment

Let’s be honest; investing in drug discovery carries risks. Absci’s partnerships have inherent weaknesses, and many projects face delays or failures. Plus, the regulatory landscape is stringent, and simply layering AI over biological processes won’t eliminate these hurdles. Furthermore, Abshi might need to issue more shares to fund its initiatives, which could unsettle some investors.

This is why I frame Abshi as a time capsule stock. The market often misjudges platforms with non-linear returns that unfold over many years. While a single drug can be appraised accurately, pricing a system that has the potential to produce numerous drugs over a decade is a much tougher challenge. For now, Absci appears to be a speculative AI biotech with a compelling narrative. By 2036, it might evolve into a larger entity controlling significant royalties and products from its platform, or it could learn why biological ventures can be resistant to sudden technological breakthroughs.